More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$268803401
EPS
0.33
P/E ratio
--
Price to sales
4.12
Dividend yield
--
Beta
1.350872
Previous close
$7.28
Today's open
$7.26
Day's range
$6.88 - $7.46
52 week range
$3.53 - $11.29
show more
CEO
Michael Amoroso
Employees
67
Headquarters
Durham, NC
Exchange
NASDAQ Capital Market
Shares outstanding
38128142
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Precision BioSciences, Inc. (DTIL) Discusses Phase 1 ELIMINATE-B Data for PBGENE-HBV in Chronic Hepatitis B Transcript
Precision BioSciences, Inc. ( DTIL ) Discusses Phase 1 ELIMINATE-B Data for PBGENE-HBV in Chronic Hepatitis B November 9, 2026 8:00 AM EST Company Participants Naresh Tanna - Chief Financial Officer Michael Amoroso - President, CEO & Director Mark Sulkowski Cassie Gorsuch - Chief Scientific Officer Conference Call Participants Man-Fung Yuen Maurice Raycroft - Jefferies LLC, Research Division Moritz Reiterer - Guggenheim Securities, LLC, Research Division Luis Santos - H.C. Wainwright & Co, LLC, Research Division Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Konstantinos Biliouris - Oppenheimer & Co. Inc., Research Division Presentation Operator Good morning, and welcome to the Precision BioSciences Investor Update.
Seeking Alpha • Nov 9, 2026

Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its review of safety data from the first patient treated with PBGENE-DMD in the Phase 1/2 FUNCTION-DMD clinical trial for Duchenne muscular dystrophy (DMD). No serious adverse eve.
Business Wire • Nov 5, 2026

Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced new and updated Phase 1 clinical data from the ongoing ELIMINATE-B study of PBGENE-HBV to be presented in a late-breaking oral presentation on Sunday, November 8 at 2:15pm MST, at the American Association for the Study of Liver Diseases (AASLD) The L.
Business Wire • Nov 5, 2026

Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the pricing of an underwritten offering of 10,235,077 shares of its common stock at a price of $7.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its common stock.
Business Wire • Nov 5, 2026

Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update. “We entered 2026 with a clear plan to deliver multiple important clinical and operational milestones this year and we have made significant progress exec.
Business Wire • Nov 3, 2026

Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the third quarter 2026 and provide a business update on Tuesday, November 3, 2026.About Precision BioSciences, Inc.Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving l.
Business Wire • Oct 29, 2026

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has been selected to deliver a late-breaking oral presentation at The Liver Meeting 2026, the 77th annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting 2026 will take place November 5-9 in Denv.
Business Wire • Oct 8, 2026

Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base.
Investors Business Daily • Sep 17, 2026

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). PBGENE-DMD is Precision's wholly owned in vivo gene editing program designed to durab.
Business Wire • Aug 24, 2026

Precision BioSciences: Promising HBV Editing Evidence
PBGENE-HBV's liver biopsy data provides unusually direct evidence that ARCUS is editing the viral reservoir in patients. Durable off-treatment viral control remains unproven, making the next ELIMINATE-B updates decisive for the investment thesis. PBGENE-DMD offers a second validation path. However, their program still lacks disclosed human safety or efficacy data.
Seeking Alpha • Aug 18, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Precision BioSciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.